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Pre-screening Report and Website 
This pre-screening report informs the Chlamydia Screening in Ireland Pilot Study 
conducted between 2007 and 2009. Further information including more detail on the 
methods and results can be found in the following accompanying reports on the 
Health Protection Surveillance Centre (HPSC) website.
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Other resources on the website include additional information on the implementation 
of screening, a toolkit for organising screening in non-clinical settings and links to 
published articles from the study. 
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Summary 
 A series of background studies in 18 to 29 year olds were conducted in a range 
of primary care settings in Dublin and Galway, 2007-09, to assess the 
acceptability and feasibility of opportunistic screening for chlamydia: 
o semi-structured interviews with 35 women who had never been tested 
for a sexually transmitted infection (STI) 
o similar interviews with 30 men and women who had had a STI test 
o a questionnaire survey of 5685 students and 400 primary care patients 
o four focus group discussions with university students 
o semi-structured interviews with eight doctors and 10 practice nurses. 
 The most important barrier to seeking or taking a STI test was the stigma 
young Irish men and women associated with chlamydia and other STIs, and 
the fear of being seen doing this.  This fear was greater among young women.  
 Young people, especially women, were aware that chlamydia infection was 
often asymptomatic and were conscious of the danger of complications such as 
infertility and the consequences of transmitting chlamydia to other women. 
 Factors that would encourage acceptance of a chlamydia screening test, which 
were common to women and men, were: 
o normalising STI testing, by portraying it as a responsible practice that 
adults should engage in  
o not being asked questions by staff about their sexual history 
o being offered screening by younger non-judgmental female healthcare 
professionals 
o being offered screening in private or general health care settings, where 
others would not be aware that they were getting an STI test 
 There was a high level of acceptance of chlamydia screening among young 
people: 95% said it would be acceptable to be offered a test, and 90% of health 
facility attendees and 75% of students said they would accept a test if offered.  
 The most acceptable setting for chlamydia screening was a General Practice 
where respondents were most comfortable with being offered screening by a 
doctor or nurse.  Other primary care settings were also acceptable, whereas 
pharmacies were not because they were seen as public settings. 
 80% said they would inform their current partner if they tested positive for 
chlamydia, though this fell to 55-60% in the case of previous partners. 
 Health care providers (doctors and nurses) viewed chlamydia screening as a 
priority, because young people are sexually active and are at high risk because 
of alcohol.  Providers anticipated high chlamydia test offers and uptake rates. 
 Providers viewed chlamydia testing as a core activity to undertake in primary 
care, but they would need support for partner notification and easy access to 
laboratory tests, especially urine-based ones. 
Conclusion: 
Most 18-29 year old men and women would respond positively if offered a test for 
chlamydia, when attending a health care facility for other reasons.  They recognise the 
risks and the importance of their sexual contacts being tested, if they themselves test 
positive for chlamydia.  However, sexual health services in Ireland need to minimise 
stigma and ensure the confidentiality and acceptability of STI testing of young people. 
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1. Introduction 
Chlamydia trachomatis is the most frequently diagnosed bacterial sexually 
transmitted infection world-wide [1]. Population prevalence of chlamydia in Ireland 
are unknown.  A 2004 systematic review of UK prevalence studies estimated that 
4.5% of women under 20 in the general population and 8-17% of women under 20 
attending sexual health services were infected [2]. 
Symptoms may include vaginal or penile discharge and dysuria.  However genital 
infection is asymptomatic in 50-88% of those infected and an estimated 46% of 
infections clear within one year [1]. Chlamydia infection is most common in 16-24 
year olds (international literature) and untreated infection has been estimated to result 
in pelvic inflammatory disease (PID), which is an infection of the female upper 
genital tract, in between 10 and 30% of women, 10-20% of whom will develop tubal 
infertility. Chlamydia trachomatis has been implicated in around 30% of cases of PID 
[3].  
A recent randomised control trial of screening in the UK found that most episodes of 
PID were in women who tested negative for chlamydia at the start of the 12 months 
[4].   
In men, Chlamydia trachomatis is the most common cause of non-gonococcal or non-
specific urethritis.  Untreated male infection can cause epididymitis, urethritis and 
Reiter’s Syndrome, a form of arthritis. It is considered biologically plausible that 
chlamydia could cause male infertility. However, there is no consistent epidemiologic 
evidence [5].  
Chlamydia is easily and effectively treated, through a single dose of an antibiotic 
(azithromycin) taken orally.  
Chlamydia screening programmes are in place in several European countries and in 
the United States of America (USA) [1]. Opportunistic screening is the most 
common model, where young men and women are invited to provide a specimen, 
when they visit a suitable setting such as their general practitioner (GP), usually for an 
unrelated reason. Large scale opportunistic screening programmes have been rolled 
out in the UK and USA [3,6] .   
Register-based screening, where eligible individuals in a target population are invited 
for screening, is being piloted in the Netherlands since 2008.  However, the evidence 
to support either approach as a population chlamydia control measure is not yet 
adequate [3,7].   
The European Centre for Disease Control guidance document on chlamydia control in 
Europe [7] has outlined a chlamydia control framework with four levels, where each 
level builds on the previous one:  
Level A primary prevention:  health promotion, school programmes and condom 
distribution 
Level B case management:  surveillance, diagnostic services, clinical services, and 
patient and partner management services 
Level C opportunistic testing:  offering chlamydia tests to people attending clinical 
settings for other reasons, so as to identify and treat asymptomatic cases 
Level D screening programme:  “This build on Level C with the addition of the 
organised provision of regular chlamydia testing to cover a substantial 
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proportion of a defined population, with the aim of reducing chlamydia 
prevalence in the population”. 
The report states that decisions on moving from one level of control to the next should 
be based on “a rigorous appraisal of the evidence for effectiveness, cost-effectiveness 
and harms”, and the aim of the guidance document is to facilitate “the development of 
local, evidence-based guidelines within the context of sound national chlamydia 
strategies.  Such strategies need to take account not only of clinical and 
epidemiological factors (such as the prevalence of chlamydia in the population) but 
also of local systems of healthcare delivery, infrastructure and resourcing” [7]. 
The Republic of Ireland does not have an organised national or regional opportunistic 
screening programme and the necessary information required to design such a 
programme was not in place. This report is the result of a two year pilot study, which 
investigated the feasibility, acceptability, effectiveness and cost-effectiveness of 
opportunistically offering screening in clinical and non-clinical settings that are 
frequented by young people.
2
  
This report presents the views of young Irish women and men who would be the 
targets of such a programme, and the views of service providers who would be 
offering screening.  The Chlamydia Screening in Ireland (CSI) Pilot Study also 
reports an analysis of the effects – numbers of persons tested, test positivity rates, 
numbers of cases and contacts treated – (Pilot Screening Programme Report) and the 
cost effectiveness of offering chlamydia screening (Economic Evaluation).  The target 
population was 18-29 year olds who were offered urine-based screening when visiting 
primary care settings or attending Third Level Higher Education Institutions 
(henceforward called HEIs or colleges).  
1.1 Overview of research project 
In late 2006, the Health Protection Surveillance Centre (HPSC), through the Health 
Research Board (HRB), invited proposals to identify the optimal model for chlamydia 
screening of men and women attending primary care or other settings in Ireland. The 
HRB specified that the study should examine the feasibility, acceptability and costs of 
a screening programme, taking into account service provider and patient perspectives.  
A proposal from a team of public health and other specialists from the Royal College 
of Surgeons in Ireland (RCSI), the National University of Ireland Galway (NUI 
Galway) and the Health Service Executive (HSE) was selected, following a 
competitive tendering process. The project, in two phases, proposed to: 
 develop a focused evidence base of public and professional perspectives on 
screening young people for a sexually transmitted infection (STI) 
 design appropriate service models based on identified enablers and barriers to 
service uptake   
 pilot and evaluate the feasibility and effectiveness of these models in a variety 
of non-specialist settings such as urban and rural general practices (GP), 
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student health units (SHU) and a family planning clinic (FPC). A non-clinical 
setting using a ‘pee-in-a-pot’ model was also proposed.   
An economic evaluation was added later. 
Challenges to be addressed included: 
 getting people (service users and providers) to engage in addressing a ‘new’ 
STI  
 convincing those at most risk (especially adolescents and those in their early 
20s, who often feel ‘invulnerable’) to accept a test in the absence of 
symptoms  
 encouraging testing across both sexes for a condition that has most direct 
impact on women (in terms of infertility) and at a time relatively far into the 
future, and 
 design screening models that take into account the constraints on primary care 
providers, genitourinary medicine (GUM) clinics and laboratories. 
Issues of acceptability to young people to be explored included: 
 whether inconvenience, cost, stigma, embarrassment, consequences of a 
positive test for one’s relationships, or denial would be barriers to uptake of 
screening; and how such barriers could be minimised/eliminated 
 preferences for or against particular health service settings for accessing STI 
screening services 
 preferences for or against primary care (GP / SHU – Student Health Unit) 
versus specialist sexual health service models for treatment and follow-up 
 preferences for or against client/patient partner notification and/or contact 
tracing models; and how barriers to the public health dimensions of 
STI/chlamydia control and service uptake can be overcome. 
The feasibility issues to be explored with health care providers included: 
 design of screening models that would meet providers’ (GPs, managers of 
SHUs and FPCs, managers in other settings) concerns around impact on 
workload  
 models of patient/client management and partner notification or contact 
tracing 
A cost-effectiveness study was added to the study through additional funding 
provided by the HPSC at the end of the pre-screening period, enabling a more detailed 
costing and economic evaluation of the processes and intermediary outcomes of the 
pilot programme, from a provider perspective.  This was conducted by economists 
based at NUI Galway. 
1.2 Challenges of screening for chlamydia in Ireland  
The Irish Study of Sexual Health and Relationships [8] had identified several 
challenges to STI control: 
1) Levels of knowledge about chlamydia are low: 73% of women and 54% of men 
reported they had previously heard of chlamydia. When questioned further, 44% of 
this group thought chlamydia was a symptomatic condition.  
5 
2) Levels of diagnosed STIs are low – 3.4% men and 1.8% women reported ever 
having had a STI, which is likely to reflect a low level of awareness of the need for 
testing for asymptomatic STIs and a tendency to feeling invulnerable [8].  
3) Increasing numbers of sexual partners, with numbers in younger age groups 
reaching levels seen in other countries, implying a likely unmet need for STI detection  
4) Social barriers to STI testing are high: younger and less educated people reported 
that it would be difficult to discuss sexual problems with a professional, with higher 
proportions of young men reporting this difficulty:  45% of men compared with 37% 
of women aged 18-24 (unpublished ISSHR data).  
Challenges identified in other research projects include: 
1) Low GP attendance rates among young males – The SLAN Study 2007 showed 
that males aged 18-29 years had lower GP attendance rates than females (53% and 
82%) [9]. This implies that opportunistic approaches need to extend beyond GP 
settings.  
2) Service capacity is limited – with a clear need for provision of additional resources 
[10]. 
3) Extensive staff training is needed: Irish GPs view STI management as the area of 
greatest need in terms of up-skilling [10].  In an ICGP report on women’s heath 
services, 68% of GPs surveyed (n=444) reported needing further education/training 
on STI management [11]. 
1.3 Epidemiology in Ireland 
Chlamydia trachomatis is a notifiable disease in Ireland. The number of notifications 
increased from 245 in 1995 to 1,278 in 2003. After 2004 when legislation requiring 
laboratory notification came into effect, the number further increased to 6,290 in 2008 
[12].  
Chlamydia trachomatis is now the most commonly notified STI in Ireland (55.7% of 
all STI notifications) [12].
 
This rise is believed to be due to a combination of factors:  
a true rise in the rate of infection, greater awareness of chlamydia infection among 
healthcare providers,, and the use of Deoxyribonucleic acid (DNA) amplification 
methods.  These methods are capable of detecting asymptomatic infection, are more 
sensitive than other methods, and can be used on specimens such as urine that can be 
collected non-invasively. 
Ireland had a crude incidence rate for chlamydia of 148.4 per 100,000 population in 
2008 [12].  The incidence rate for the Western area (former Western Health Board) 
where this screening project was piloted was 127.7. The majority of notified cases of 
infection in Ireland (61%) are among 20–29 year olds. People aged 0-19 years and 
those aged 30-39 years each account for 13% of notifications.  The limited published 
Irish prevalence/positivity data are summarised in Table 1. 
6 
Table 1. Published studies on chlamydia prevalence and positivity rates in Ireland 
Males: Prevalence CT Significant risk factors 
Males attending out patient 
service or third level sports 
arena [13] 
5.9% (95%
 
CI: 3.6- 8.2)  >1 sexual partner in 
the last 6 months,  
 >8 lifetime partners,  
 Current symptoms  
 
Females: 
Female HEI students 
attending 3 SHUs [14] 
4.8% (95% CI: 3-7)  Current suggestive 
symptoms, 
 2/> one-night stands  
 3 or >lifetime sexual 
partners. 
Females attending 
antenatal, infertility 
clinics
 
and family 
planning clinics [15] 
3.7% (35/945) with 11.2% 
(22/196) in those aged < 
25 years 
 Single-status  
 Age <25 years 
Combined positivity rates 
STI clinics [16]  9.5% 
 
 
The Well Woman Centre   
[17] 
Range 1-20%* 
20% found in women aged 
< 20 years of age. 
*Note: This includes asymptomatic 
and symptomatic cases 
 
 
Major knowledge gaps in the epidemiology of chlamydia in Ireland include: 
 Prevalence rates in important populations are unknown:  GP attendees, women 
not attending healthcare services, prisoners and men etc. 
 Risk factor data to guide selective screening programmes. 
1.4 Rationale for screening 
Chlamydia trachomatis infection of the genital tract is of public health importance. 
Because most cases (50-88%) are asymptomatic, the infection is transmitted sexually 
without the knowledge of either partner.  Those infected do not seek investigation and 
treatment, and potentially severe long-term complications can occur, such as: 
 Tubal infertility in women due to pelvic inflammatory disease (PID) and possibly 
male infertility due to epidymo-orchitis. 
 Chlamydia infection during pregnancy can cause miscarriage or premature birth. 
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 Babies born to mothers with infection of their genital tract may develop 
chlamydia eye infection within a week of birth (chlamydia ophthalmia 
neonatorum), and may subsequently develop pneumonia. 
 Increased risk of transmission of Human Immunodeficiency Virus (HIV). 
What is screening? 
Screening is a process where unrecognised disease is identified by tests that can be 
applied rapidly on a large scale. The UK National Screening Committee has identified 
criteria for any screening programme [18]. 
The general benefits of screening are: 
 Where screening test positive: 
o Less radical treatment due to early diagnosis 
o Improved prognosis for some 
 Where screening test negative: 
o Reassurance. 
However, it is important that people have realistic expectations of what a screening 
programme can deliver. Screening can reduce the risk of developing a condition or its 
complications, but it cannot offer a guarantee of future protection. Screening comes at 
a cost, especially from the perspective of whoever is paying for the screening – and 
more broadly for whoever is paying for the health service where the screening is 
offered. Other costs can also be incurred by the person offered the screening, 
especially if the disease being screened for is a STI that can have stigmatising effects. 
1.5 Screening in other countries 
In Sweden, opportunistic chlamydia screening and mandatory partner notification 
have been widespread since the 1980s, although not organised at a national level. 
Initially declines were seen in rates of diagnosed chlamydia, PID and ectopic 
pregnancy. However, surveillance data show rising rates since 1997 [7]. 
In England, chlamydia screening was introduced in 2003 and rolled out across the 
country in three phases by 2007. Screening tests are offered opportunistically to 
sexually active women and men aged below 25 years old attending selected healthcare 
settings, including pharmacies and contraceptive clinics, and through outreach 
activities at universities, sporting events and prisons [6].  By late 2008, 370,000 
screening tests had been reported, 29% of which were in men.  Staff of the National 
Chlamydia Screening Programme, based at the Health Protection Agency in London, 
advised on this Irish pilot study. 
In the United States, there are organised chlamydia control activities with national 
coverage that show characteristics of screening programmes [19]. The infertility 
Prevention Programs in the ten Health and Human Services Regions aim to offer 
chlamydia screening to young women less than 26 years old, attending public family 
planning clinics [7]. 
In Europe, six countries offer opportunistic testing but to different groups. For 
example, in Iceland chlamydia testing is offered to women who have an abortion. 
Nine countries are planning opportunistic screening programmes compared with one 
(Norway) planned as a proactive, register based programme [7].  
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Systematic, population-based register screening is being rolled out to target 315,000 
16-29 year olds in three regions of the Netherlands since 2008, using a cluster 
randomised study design (2007-10).  In the first year, participation rates of 16% were 
achieved (lower in men and in lower age groups). 
1.6 Chlamydia Screening in Ireland Pilot Study 
This report summarises most of the findings of the pre-screening research conducted 
in Ireland between 2007 and 2009.  It consisted of a series of sub-studies focusing on 
the acceptability and feasibility of opportunistic screening from the perspectives of 
service users and service providers in different settings in Dublin and Galway.  An 
opportunistic screening model was designed and tested because the absence of a 
unique identifier for health service users in Ireland precluded a systematic or register-
based screening approach. 
Qualitative followed by quantitative studies were undertaken with health service users, 
and potential users in the case of students across seven HEIs (Third Level institutions) 
in Ireland who completed an intranet questionnaire. The results of the Pre-screening 
Study informed the design and roll out of the pilot screening programme in Galway.  
The rationale for this approach was that an understanding of the factors that would 
prompt people to accept or not accept the offer of a test for a sexually transmitted 
infection (STI), and the factors that would influence providers to offer or not offer at 
test, were fundamental to the design of a screening programme.   
The project which commenced in 2007, was designed and implemented by a Steering 
Group (core and expanded groups), comprising staff at the RCSI, NUIG and HSE, 
guided by an National Advisory Group (see Summary Integrated Report). 
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2. Methodology  
The target population for the pre-screening studies were young adults aged between 
18 and 29 years, which was the age range with the reported highest prevalence of 
chlamydia in Ireland and had shown the greatest increase in incidence of STIs in the 
previous decade. Legal advice precluded the inclusion of those under 18 years in the 
pilot study. 
Ethical approval was obtained for the studies from the following committee: 
 Irish College of General Practitioners 
 Royal College of Surgeons in Ireland 
 University Hospitals, Galway  
 National University of Ireland, Galway 
 Dublin Institute of Technology  
2.1 Interviews with young women who had never had an STI test 
Semi-structured interviews were conducted with 35 women aged 18–29 years who 
were recruited from six GP settings and two Family Planning Clinics (FPCs):  two 
GPs and one FPC in Dublin; and three GPs (two urban and one rural) and one FPC in 
Galway.  Settings were purposively selected based on: a) being typical of settings and 
target groups that would be likely to offer opportunistic screening if it was introduced 
in Ireland; and b) willingness of staff to facilitate the study.   
Health service managers (GPs or practice nurses) in each setting provided eligible 
young people visiting the service with an information sheet, which included contact 
details of the interviewers for them to get in touch with, if they were willing to be 
interviewed.   
2.2 Interviews with service users who had previously attended STI 
services  
Semi-structured interviews were conducted with 30 young adults (21 women, 9 men) 
who had previously attended health services for STI testing in Ireland.  Respondents 
were recruited from GP practices, Student Health Units (SHUs) in two Higher 
Education Institutions (HEIs), FPCs and specialist STI treatment services for men 
who have sex with men (MSM).   
A researcher trained in qualitative methods undertook 30 of the 35 interviews in 
primary care settings – the rest were conducted by a public health specialist.  The 
same researcher conducted all of the 30 interviews with STI service users.  
The objectives of these interviews were:  
a) to identify, explore and understand - 
o the factors that would encourage or deter young people from accepting an 
offer of screening (2.1) 
o STI service users experiences with primary care (GP and FPC) and 
specialist genitourinary medicine (GUM) STI services (2.2) 
b) to inform the design of structured questionnaires (2.3)  and 
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c) to use young people’s perspective in the design of health promoting messages 
to encourage young people to accept screening. 
Interviews lasted 60 minutes on average, were tape-recorded (with respondents' 
permission) and transcribed. Thematic analysis was conducted by the qualitative 
researcher using standard methods, with coding and the results of the analysis 
reviewed by at least one other researcher. 
2.3 Self-administered structured questionnaire survey of 18-29 year olds 
A short structured self-administered questionnaire and information sheet were 
designed by the Steering Group and piloted in one HEI. They were delivered on-line, 
using ‘survey monkey’, to students in five other HEIs in the Republic of Ireland. The 
mode by which the student body was made aware of the survey varied.  The most 
effective method was when students were sent a circular email by the College 
authorities, which contained a hyperlink to the online version of the questionnaire 
A similar information sheet and questionnaire with additional questions on factors that 
might influence respondents’ decision on screening was piloted in a GP practice.  A 
survey was then conducted of eligible 18-29 year olds attending 13 GP practices in 
the West of Ireland (9 rural and 3 urban), one college health practice and one GUM 
Clinic. This was a convenience sample and refusal rates could not be calculated 
(Practice staff handed eligible attending patients a survey pack, including an 
information sheet and questionnaire; and were unable to identify who did not 
complete the questionnaire.   
Recruitment continued until 400 responses (completed questionnaires) had been 
obtained.  
These surveys measured respondents’ views and preferences on the acceptability of 
chlamydia screening, preferred settings, preferred type of person to offer them the test, 
preferred methods of receiving test results and (if necessary) treatment, preferred 
method of notifying partners if test positive, and willingness to pay for screening.  
The resulting data set was imported into SPSS for analysis. 
2.4 Focus groups discussions with third level students 
It was decided to design, implement and evaluate a ‘pee-in-a-pot’ programme in two 
HEIs.  There, students would have the opportunity to be screened for chlamydia 
during these colleges’ sexual health awareness weeks for students. 
Students were invited to participate in focus group discussions in each college, to get 
their views on how best to offer ‘pee-in-a-pot’ screening to students, outside of 
clinical settings.  Recruitment was assisted by the local Student Unions and email 
advertisements through the student intranet.  
Focus groups were conducted by the research health advisor (RHA) and a public 
health specialist based in the Galway region. All participants were volunteers and 
received a €10 voucher for their participation in the discussion. Group sizes were on 
average 8-12 and group discussions were held on campus.  One male and two female 
group discussions were held in two different college campuses.  Discussions were 
audio-recorded and transcribed; transcripts were analysed and conclusions were 
drawn which helped to inform and finalise the ‘pee-in-a-pot’ event and material 
(screening packs) design. 
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2.5 Pre-screening interviews with healthcare providers 
Health care professionals based in the Galway region, where the pilot study was 
planned, were purposively invited to participate in tape-recorded semi-structured 
interviews, which were conducted by the research health advisor.  The purpose was to 
inform the screening models and explore providers’ views of chlamydia screening in 
primary care. A topic guide based on relevant literature was used to guide the 
interviews, which were transcribed and thematically analysed. 
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3. Findings 
3.1 Interviews with young women who had never gone for STI testing 
The most important barrier articulated by these 35 women was the stigma that they 
associated with chlamydia and other STIs. Most respondents had generally 
conservative opinions about how they wanted opportunistic screening services to be 
offered, preferring that they be located in traditional medical settings (e.g. GP 
practices) and to be offered screening by trained medical personnel.  
Factors that would encourage them to accept screening included; 
 Provision of free screening  
 Normalizing screening (not offering screening on a risk factor basis),  
 Being offered screening by younger non-judgmental female healthcare 
professionals 
 Communicating to students that accepting an offer of chlamydia screening is a 
positive, healthy and responsible practice.  
 Offering screening in private places (for more on these young women’s 
screening location preferences see: 
http://www.ncbi.nlm.nih.gov/pubmed/19744875). 
These characteristics would serve to frame chlamydia screening as a normal ‘check-
up’ activity undertaken by responsible individuals, and would serve to counteract the 
opposite interpretation (which they feared), which was that screening is a potentially 
stigmatizing activity undertaken by individuals with risky lifestyles.  
Offering screening on a risk factor basis, that is if they were asked questions about 
their numbers of sexual partners and any risky behaviours, would make these young 
women less likely to accept an offer of screening (for more on young these young 
women’s attitudes towards risk factor screening see: 
http://www.informaworld.com/smpp/content~db=all~content=a921626572~frm=titlel
ink?words=balfe&hash=3210076980). 
Respondents’ partner notification preferences were in line with those expressed in 
other international qualitative studies. Most respondents’ indicated that they would 
prefer to inform their current partners themselves if they tested positive for chlamydia. 
However, they also acknowledged that they would be less likely to inform their 
previous partners, demonstrating the importance of embedding contact tracing in any 
opportunistic screening programme (more on respondents’ partner notification 
preferences is said at: http://www.biomedcentral.com/1471-2458/10/425).  
Young women spoke of the importance of partner notification in terms of the 
damaging effects that refusing to inform ex-partners could have on other women who 
had sex with their ex-partners, and the possible consequences on these women’s 
fertility. They generally empathized more with other young women than with men 
(including their male partners).  This suggests that the benefits to other young 
women’s fertility (as well as their own) could be used as a way to promote partner 
notification among women with STIs. 
Young women were not homogeneous in their attitudes towards screening and 
screening barriers: younger women (in their teens) and those from working class and 
rural areas had particularly strong STI-related stigma concerns.  Some young women, 
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especially those in rural areas, feared that if they presented to their local GP with fears 
or symptoms suggestive of a STI, this could evoke a negative judgemental reaction, 
especially if he was an older man.   
Anxieties about confidentiality and stigma were a major concern.  Young women 
recruited in urban GP practices, especially, feared getting a reputation among their 
peers as promiscuous, if they were seen to be frequenting a setting where STI 
screening was on offer.  In rural areas, young women expressed concerns about 
possible breaches of confidentiality, if the GP or practice staff knew their parents. 
These findings pointed to the importance of provider training and education, and of 
the configuration of the clinical (and any non-clinical) settings where screening is 
offered to young women, so as to minimise and avoid the risk of stigma.  In situations 
of limited resources, one might target resources at removing stigma barriers that deter 
at-risk young people from using primary care as well as GUM services for their 
sexual health needs.  
Generally, a GP or family planning clinic delivered service was preferred by young 
women, some of whom expressed a preference to be informed and offered screening 
by young female doctors and nurses, who were seen as less likely to be judgemental.  
Screening offers in pharmacies and by non-clinical professionals or receptionists, 
where confidentiality could not be assured, would be a disincentive to accepting 
screening. 
3.2 Interviews with service users who had previously gone for STI 
testing  
Five test-promoting factors were identified from these interviews with these 21 
women and 9 men.  
(i) Viewing STI testing as a responsible practice that adults should engage in. 
(ii) Having a protective orientation towards partners and other young adults. All 
respondents’ indicated that they would experience significant guilt and distress 
if they transmitted an STI to another individual. STI transmission was viewed 
as a fundamentally unjust activity. 
(iii) Both male and female respondents were concerned about the damage that STIs 
could do to their future fertility, indicating awareness of important 
complications in this at-risk group. STI testing was seen a crucial means of 
protecting this fertility. 
(iv) Perceived risk status of respondents’ sexual partners.  Partner’s risk was 
assessed by a range of characteristics, including appearance, geographical 
origin, and past sexual history. 
(v) Those who did not have symptoms when they attended testing expressed 
anxieties about the risk that asymptomatic STIs (especially chlamydia) could 
affect them without their knowledge.  Anxieties about symptomless STIs 
stemmed from two sources: consciousness-raising health promotion materials 
and knowing other individuals who had been diagnosed with STIs (more 
information on test-promoting factors for these young adults is contained at 
the following link: http://www.biomedcentral.com/1471-2458/9/311). 
Based on these interviews, in the screening pilot we emphasized to young people that 
screening was a positive and healthy activity that was beneficial to society; that STI-
related risk could not be visually detected and assessed; and that they young people 
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could have STIs without them being aware of it. These messages were intended to 
promote screening uptake by young adults. 
Despite the benefits that these respondents associated with STI-testing, they were also 
concerned about STI-related stigma. These were often very careful about how they 
accessed information about STIs and STI testing (concerned about the risk of other 
people seeing them doing so), and often sought STI testing in venues where they felt 
that they would by unlikely to run into people whom they knew, because STI testing 
was (for them) a secret, hidden activity. They often described feeling very self-
conscious while accessing STI-testing facilities (more on these young people’s 
feelings of self-consciousness and stigma is found at this link: 
http://www.biomedcentral.com/1756-0500/3/229).  
Respondents felt especially self-conscious while waiting in clinic waiting rooms. 
Most kept their STI testing practices secret from other people, including families and 
friends, so that they could manage stigma and continue to maintain their social 
identities as ‘normal’ individuals. Keeping their STI testing practices a secret from 
was often difficult and emotionally draining.  
Healthcare professionals were one of the few groups to whom respondents felt 
comfortable disclosing their need for STI testing.  However, about one third of them 
reported experiencing stigmatizing reactions from healthcare professionals, which 
made them reluctant to seek treatment for their STI. Conversely, there was also 
evidence that healthcare professionals who put an effort into making respondents feel 
secure and at ease could have a positive impact on respondents’ interpretation of the 
STI-testing process, and reduce their feelings of shame, stigma and embarrassment. 
3.3 Self–administered structured questionnaire survey of 18-29 year olds 
In the primary care settings, 400 18-29 year old respondents were recruited: 306 
(76%) females and 144 (24%) males, with an average age of 24 years.  In the intranet 
survey, 5685 students participated: 3400 (60%) females and 2285 (40%) males, with 
an average age of 21 years. 
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Table 2. Sexual behaviour and risk factors 
Question Students 
 
Males 
Intranet 
 
Females 
Primary 
 
Males 
Care 
 
Females 
 
Had sex in the past year 
 
n     (%) 
 
n     (%) 
 
n (%) 
 
n (%) 
with 1 partner only 709 (40.2%) 1599 (52.9%) 18 (32.1%) 176 (65.2%) 
with 2 or more partners 657 (37.2%) 775 (25.6%) 31 (55.4%) 68 (25.2%) 
No 280 (15.9%) 469 (15.5%) 2 (3.6%) 19 (7%) 
-Prefer not to say 
 
118 (6.7%) 180 (6%) 5 (8.9%) 7 (2.6%) 
Had sex with new partner 
in last 3 months 
 
n (%) 
 
n (%) 
 
n (%) 
 
n (%) 
Yes 600 (34.1%) 684 (22.6%) 31 (55.4%) 52 (19.2%) 
No 1066 (60.6%) 2200 (72.8%) 20 (35.7%) 211 (77.9%) 
-Prefer not to say 93 (5.3%) 136 (4.5%) 5 (8.9%) 8 (3%) 
Respondents differed from the population-based Irish Study of Sexual Health and 
Relationships (ISSHR 2006 ) survey in some important respects, notably: 32% of the 
chlamydia survey respondents (students and primary care attendees) reported two or 
more sexual partners in the previous year compared with 21% of ISSHR respondents 
who responded positively to the same question.   
The difference in reported sexual behaviour by sex, in this study, was most marked in 
primary care settings, where male respondents (55%) were more than twice as likely 
as female respondents (25%) to have had sex with two or more partners in the 
previous year.  A quarter of female respondents reported this risk factor in both 
surveys and 37% of male students reported two or more sexual partners in the 
previous year. 
Willingness to be screened:  
Around 95% of students and healthcare attendees reported that they would find it 
acceptable to be offered chlamydia screening and most (75% of students and 91% in 
healthcare settings) would accept a screening test if offered one (see Table 3): 
There were some differences in the responses between the two samples and between 
male and female respondents, which were sometimes statistically significant. For 
example, those already attending a health care setting and women expressed more 
positive views about chlamydia screening than did students and men.  However, the 
differences were generally small.  
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Table 3. Willingness of respondents to be screened for Chlamydia. 
Question Students Healthcare 
facility 
attendees 
P value 
(students 
v. patients) 
Males Females  
 
P value 
 
Chlamydia test 
acceptable to  
 
n (%) 
 
n (%) 
 
 
 
n (%) 
 
N (%) 
(males v. 
females) 
-Yes  
4682 (94) 
 
382 (96) 
Chi= 4.9; 
p= .087 
1881 (96.2) 3183 (92.9) Chi= 31; 
p= .000 
-No 72 (1.4) 7 (1.8)  28 (1.4) 
 
51 (1.5)  
-Undecided 228 (4.6) 9 (2.2)  46 (2.4) 191 (5.6)  
 
Would take a 
Chlamydia test 
if offered one? 
      
-Yes 3632 
(75.5) 
358 (90.9) Chi= 48; 
p= .000 
1343 (72.1) 2647 (79.3) Chi= 36; 
p= .000 
-No 534 (11.1) 14 (3.5)  
 
 
247 (13.3) 301 (9)  
-Undecided 643 (13.4) 22 (5.6)  273 (14.6) 392 (11.7)  
Attendees were asked with respect to a range of factors if each would ‘affect your 
willingness to take a test’. For each factor, more than three quarters of respondents 
reported that it would not (negatively) affect their decision to accept a screening offer. 
The most common factors that might deter them were: cost (24% of respondents), 
embarrassment (22%), having to tell their current partner (17%) or tell a previous 
partner (12%), inconvenience (14%) and worry (12%).   
Primary care attendees were generally more positive about paying for a chlamydia 
test: 65% said they would and only 17% said they would not pay.  Students were more 
equivocal:  only 44% of students reported that they would take a chlamydia test if 
they had to pay for it, 25% said they would not and 31% were undecided.  
Preferred setting and ‘screener’: 
When offered a choice, one’s own home was the preferred setting for taking a test as 
expressed by 50% of students and 48% of health service attendees.  This was followed 
by testing at a health care setting (36% of students and 44% of attendees), and taking 
a test in either setting (10% and 6%).   
There was a reluctance to be tested in a non-health care setting (ie. workplaces, gyms 
and concerts), which was only acceptable to 4% of students and 2% of health care 
attendees.  Women’s and men’s responses were similar, with the former the most 
negative about non-health care settings (1% and 3%).   
Respondents were asked about the acceptability of different health care settings for 
screening (see Table 4).  GP practices were acceptable to primary care attendees 
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(61%) and students (68%), who also reported student health services as acceptable 
(69%).  GUM / STI clinics were generally acceptable to the students (56%), though 
less so to those respondents who were recruited in primary care (20%) 
Table 4. Preferred settings for screening 
Settings where 
screening 
services should 
be located: 
Students 
 
 
 
n (%) 
Health 
care 
facility 
attendees 
n (%) 
P value 
(Students 
v. health 
care 
 
Males 
 
 
 
n (%) 
Females 
 
 
 
n (%) 
P value 
(Males vs. 
females 
 
 
GP  3875 (68.2) 243 (60.7) 
 
Chi= 9; 
p= .003 
1524 (64.1) 2594 (70) Chi= 23; 
p= .000 
Family 
planning  
2779 (48.9) 85 (21.3) 
 
Chi= 113; 
p= .000 
713 (30) 
 
2151 (58) Chi= 457; 
p= .000 
GUM/STI 
clinic  
3189 (56.1) 84 (21) 
 
Chi= 183; 
p= .000 
1106 (46.5) 2167 
(58.5) 
Chi= 83; 
p= .000 
Gay men’s 
health clinic 
1360 (23.9) 32 (8) 
 
Chi= 53; 
p= .000 
471 (19.8) 
 
921 (24.9) Chi= 20; 
p= .000 
Student health 
clinic 
3939 (69.3) 81 (20.3) 
 
Chi=399; 
p= .000 
1419 (59.6) 2601 
(70.2) 
Chi= 71; 
p= .000 
Pharmacist  405 (7.1) 
 
36 (9) 
 
Chi= 1.7; 
p= .194 
175 (7.4) 
 
266 (7.2) Chi= .045; 
p= .833 
Respondents were asked separately about the acceptability of a Pharmacy or 
Chemist’s premises as a setting for screening.  Most (230 or 57% of) primary care 
attendees had used a Chemist in the previous year, but only 27 (12%) of these 
considered this a suitable setting for screening.  Only 189 (5% of) students reported 
having used a Chemist in the previous year (almost all [182] of these were female 
students).  Only 13 (7%) of these considered this a suitable setting for screening.   
The great majority of respondents (70-80%) had a preference for a health professional 
(doctor or nurse) to offer them screening; and around 95% said that they would not be 
comfortable if it was receptionist who made the offer. About two thirds of female 
respondents among both groups preferred a female health professional to offer them 
the screening test, whereas a similar proportion of male respondents had no gender 
preference.   
Receiving results and treatment 
A range of options were offered to respondents for receipt of a negative result, among 
which a ‘mobile phone call’ was the most popular (33-35%), followed by email (16-
25%), with SMS text (9-10%) less popular than the person phoning for the result (15-
20%).   
In the case of notification of a positive result, respondents indicated a strong 
preference to be called on their mobile phone (50-53%), with far fewer (5-7%) opting 
for a text.  Most respondents (59-60%) preferred to call in to the GP or nurse to 
receive their treatment, with fewer (22-26%) preferring to have the prescription 
posted out to them. 
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Partner notification preferences 
Similar proportions of both sets of respondents reported that they would be willing to 
have their current partner informed if they themselves were diagnosed with chlamydia 
(77-82%); and most (87-88%) would prefer to tell their current partner themselves 
about the result. 
There were lower response rates across the two samples with respect to informing 
previous partners (53-59%) and to taking responsibility for telling previous partners 
themselves (54-60%).  60% of students and 76% of primary care attendees reported 
that they would be happy to receive reminders about attending for chlamydia 
screening. 
3.4 Focus groups discussions with third level students 
The findings of the one male and two female focus groups held on the two HEI 
campuses are as follows, and are consistent with the findings of the qualitative and 
structured interviews. 
Offering the test 
When participants were asked about how they would feel about being offered a 
screening test by their local GP, most felt it would provoke ‘a mixed reaction’ such 
as: ‘why are they asking me?’ However, most participants felt it was acceptable to be 
offered a test during a general consultation, if accompanied with an adequate 
information leaflet.  
The doctor’s communication style was perceived as important, with participants 
preferring an encouraging supportive approach as opposed to being instructed to take 
a test. Framing the test offer as being part of a wider official screening programme 
was considered important.  
Participants reported feeling sensitive to provider perceptions of them if they accepted 
the test offer. Male participants discussed their anxieties about taking the test, which 
were mainly about the perceived invasive nature of testing methods.  
The information gap 
Lack of information about chlamydia and testing methods was perceived to be a major 
barrier in preventing young men in particular from taking the test. Male participants 
reported, being self-conscious about reading educational material in public areas such 
as a GPs ‘waiting rooms. Participants agreed that perceptions about STIs were often 
based on what is portrayed on TV which is often ‘not an educated view’, where STIs 
are ‘blown out of proportion’.  
Partner notification 
While both male and female focus groups raised similar concerns about telling 
previous sexual partners of their diagnosis, female participants were more likely to tell 
previous partners. Whereas, their male counterparts reported less feelings of 
responsibility for previous sexual partners. The main deterrents for male participants 
were unease associated with telling previous partners and potential threats to personal 
relationships.  
These students had misinformation and held misconceptions about partner notification 
and were unsure of the methods of contact that were available to them. Fears about 
having to supply contact details on sexual partners to providers was especially 
prominent for males. For men, this would be a deterrent to accepting testing.  
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Settings 
Participants reported the best place to offer screening was general practice or student 
health services.  Male participants in particular felt a screening programme was more 
likely to be successful in a student health setting, because many participants would 
not want to attend their local GP for a STI test. Fears around compromised patient 
confidentiality and an ‘over familiarity’ with local GPs were discussed.  
During the focus groups participants were distributed sample testing kits that could be 
used for a potential screening campaign in third level institutions. When asked about 
offering screening around student campuses, respondents perceived this to be ‘a good 
idea especially during the sexual health and awareness week’.  Participants felt 
screening on-campus would be a good way to ‘raise awareness’.  
Privacy  
Many students stressed the need to preserve participants’ privacy as it was important 
for participants to maintain their privacy in front of their fellow peers – testing was 
perceived to be ‘a private issue’. Participants felt having testing kits available in 
toilets could minimise testing being ‘so public’ and could be ‘a very confidential way’ 
of conducting the screening.  
Anonymous testing 
Participants discussed the need for testing packs to be ‘simple and clear’ with 
minimal information so that students could read them quickly. Having the testing 
anonymous was seen as pivotal to the success of any programme as ‘students would 
simply not go for it’ if they have to give name or addresses.  
When asked about receiving test results, participants deemed it acceptable to give 
their mobile phone number for negative test results to be texted (this was different to 
the response in the student intranet survey). Language and wording needed to be 
tailored to protect participant’s privacy.   
Other non-clinical settings 
Other innovative approaches were explored with participants such as posting testing 
kit packs and outreach screening in social entertainment setting such as pubs. 
Responses to these strategies were lukewarm or negative particularly in relation to 
entertainment settings with most feeling this was impinging on their privacy and 
inappropriate to these events. Participants were concerned that there would be high 
alcohol consumption and that these venues were simply too public for testing.  
Views on health promotion materials 
Students wanted health promotion materials to be made ‘real and relate to people’s 
lives’. Materials and messages needed to be presented in a positive way with the use 
of ‘light hearted’ and informal approaches being a good way to attract attention. 
Participants felt the most important messages for advertising a screening campaign 
were that it was ‘free, easy and confidential’. The use of media such as local radio and 
posters were seen as important mediums to advertise screening. 
3.5 Pre-screening interviews with health care providers 
Eighteen providers were interviewed: eight doctors and ten practice nurses from 
general practices, student health units and family planning clinics. Overall, there was 
widespread recognition among providers on the need for and benefits of screening in 
the target population (18-29 years).  
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Providers were concerned that this age group was particularly vulnerable to infection 
due to high risk lifestyles. Young people were seen by providers as being ‘very 
sexually active’ with high alcohol consumption and low levels of responsibility 
regarding safe sexual practices. Approaching the topic sensitively was seen as crucial 
to avoid causing offence to patients. Most providers felt the screening test offer 
should be integrated into a general consultation.  
Potential barriers to recruitment 
Just under half of participants felt that partner notification was a barrier to any 
screening programme in primary care. Lack of resources such as time and personnel 
would prevent effective and comprehensive partner notification.  
Many providers also reported lack of time as a potential barrier to offering the test 
during busy clinic schedules. Counselling patients and explaining the consequences of 
a positive result during the consultation was seen as labour intensive and time-
consuming.  
Three providers felt that offering testing to male patients was more difficult than with 
their female counterparts as young men ‘rarely attended general practice’. Providers 
were enthusiastic about urine testing as a fast and efficient testing method, especially 
for males.  
Anticipated high screening rates  
Providers were optimistic and enthusiastic about anticipated screening rates, 
especially among women, prior to the pilot screening programme. Providers 
commonly reported seeing a large proportion of the target age group and anticipated 
high uptake in patients. Five providers, who agreed to participate in the screening 
pilot, anticipated fifty screening tests per month, six providers anticipated twenty to 
forty screening tests per month and one student health unit predicted ‘200 a month 
minimal’. 
Test results  
While providers had varied systems and protocols for giving test results to patients, 
most felt ‘a medically trained’ member of staff is the most appropriate person to give 
results. The trained personnel could either be nurses or doctors but most providers 
favoured that the person who had initially offered the test should give the test result.  
All providers believed that patients who tested positive should return to the place of 
testing for treatment and follow-up. While a minority of providers felt a doctor was 
the most appropriate person to give positive results, many agreed the nurse could 
easily give results if trained and comfortable doing so. 
Overall, participants agreed that patients should be given a choice on how they would 
like to receive their test results. A third of providers considered that sending text 
messages was an acceptable method for results- this was based on the use of suitable 
wording and measures to protect patient identification.  
Treatment  
The majority of the providers felt the doctor or the nurse was the most appropriate 
person to give health advice. Lack of confidence in dealing with sexual health issues 
was perceived as a barrier for many. The remaining five providers felt ‘a trained 
health advisor with a bit more of a background’ was required for any future 
programming.  
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Partner notification  
Based on the interviews, the extent to which partner notification was being carried out 
in general practices appeared to be limited. Most were not willing ‘to take it on board’ 
without further resources (for example, time, funding and support of health advisor) 
and training.  
STI testing  
There were varied practices amongst providers with respect to further STI screening 
of patients who tested positive for chlamydia. Most did not routinely screen for other 
STIs. The majority of providers stressed their preference for referring patients to the 
GUM clinic where they would receive a more ‘comprehensive service’.  
Additional resources  
When asked about what additional resources providers might need if chlamydia 
screening was introduced, several participants stated that time was the biggest barrier. 
Extra resources such as personnel and funding were also listed as high priorities. 
While training needs for providers were diverse, training on partner notification 
methods was the main area of concern.  
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4. Discussion and Conclusions 
The current levels of chlamydia control in the Republic of Ireland corresponds most 
closely with Level A and Level B, as outlined in the ECDC Guidance on Chlamydia 
control in Europe [7].   
Elements of primary prevention (health promotion and education) are in place, 
through national health services (for example HSE and Crisis Pregnancy Agency).  So 
also are elements of Level B:  
 surveillance (through Laboratories, Departments of Public Health, clinicians 
and the Health Protection Surveillance Centre),  
 case management at GUM and Family Planning Clinics and in some GP 
practices, and 
 diagnostic and partner management services, though access to the former is 
limited and urine-based testing is not available in all areas while the latter are 
generally restricted to GUM Clinics. 
The population-based Irish Study of Sexual Health and Relationships [8] survey 
reported that 3.4% of men and 1.8% of women reported having ever been diagnosed 
with a STI, with the highest life-time rates in 25 to 34 year olds (5% of men and 4% 
of women), and in 35-44 old men.   
These rates place “Ireland outside and below the usual range of rates reported in 
Knowledge Attitudes and Beliefs surveys. In the international context, this age pattern 
is unusual.  The peak prevalence usually occurs later, since older respondents have 
had more time to acquire an STI.  Older Irish people have unusually low numbers of 
sexual partners. . .” [8].   
Historical rates of reported STIs in Ireland are low, compared to other European 
countries (ECDC 2009).  However, large rises in reported STIs – a 60% increase in 
reported cases of genital chlamydia (from 3144 in 2006 to 5023 in 2007) and a 
doubling in reported cases of genital herpes (from 455 to 988) – may point to a 
rapidly changing picture and a ‘catch-up’ phenomenon in young Irish men and 
women, in their teens and twenties [12], and compliance with recent legislation 
requiring laboratories to notify all cases.  Increased awareness and testing by health 
professionals is likely to account for only part of this new picture. 
This report provides an evidence-base with respect to the acceptability, and preferred 
options around the delivery, of chlamydia screening services, from the perspective of 
18-29 year olds who have used and those who have not used STI services.  The 
findings of the qualitative and structured survey studies show a similar picture, and 
both are consistent with the findings of ISSHR.  These can be summarised as follows: 
 Most young people in Ireland are sexually active.   
o Two or more sexual partners in the previous year were reported by one 
fifth (ISSHR) to one third (in the CSI) of respondents.   
o One half of the students and 60% of the GP and health clinic attendees 
reported one sexual partner in the previous year.   
o One quarter of both groups of 18-29 year olds had had sex with a new 
partner in the previous three months (CSI). 
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 Despite the changes in sexual activity, young people in the CSI perceived 
sexual attitudes in Ireland to be conservative.  They expressed high levels of 
fear around being stigmatised, if they were seen to be visiting a setting 
designated for the delivery of STI diagnosis and care.  They also expressed 
concerns about the confidentiality of the services, including their local GP, 
where chlamydia and other STI screening might be made available 
 The great majority of young people aged 18-29 years: 
o would find it acceptable to be offered a chlamydia test, especially a 
urine based one 
o would accept one if offered, and 
o only want the test to be offered by a non-judgemental health worker 
(doctor or nurse) in a confidential setting 
Factors that would encourage them to accept screening included provision of free 
screening and the normalizing of screening, that is a service where they were not 
asked about risk factors such as numbers of sexual partners.  Some stressed the 
importance of staff highlighting that accepting an offer of chlamydia screening is a 
positive healthy and responsible practice.  Most said they would prefer to inform their 
current partners themselves if they tested positive for chlamydia.  However, they were 
less likely to inform previous partners, which highlighted the need for contact tracing 
in a screening programme. 
In summary, the data demonstrate a generally positive attitude to chlamydia screening 
among young people in college settings and while attending a range of primary care 
health service settings, and a large unmet need for sexual health services.  Positive 
attitudes (95%) and intentions to accept chlamydia screening if offered (76-91%) 
would not necessarily translate into high screening uptake in these settings.  Overall, 
target population coverage in the English National Chlamydia Screening Programme 
was estimated at 4.9% [6]; and “in contrast to predicted uptake of 50%, only 2.5% of 
16- to 24- year olds were screened” over the course of one year [3]. 
The findings of the Pre-screening Study have produced a body of useful advice for 
planners and health care providers, especially GPs and other primary care providers, 
on how to configure services. They also highlight the importance and need for 
provider training, especially on the human dimensions of STIs and how they affect 
young people’s health care seeking behaviour.  Despite, sexual behaviour and rates of 
STIs that are approaching those of Ireland’s European neighbours, young Irish women 
and men feel vulnerable and at risk in visiting health care settings with their sexual 
health concerns.  
Providers (doctors and practice nurses) expressed support for chlamydia screening in 
young people, enthusiasm about participating in pilot screening for chlamydia, and 
optimism about the numbers of young people they could recruit.  However, they also 
expressed concerns about the likely workload and reckoned that partner notification 
was the component of screening where they would most need support, preferably 
through the provision of a dedicated health advisor.  They anticipated that it young 
men would be more difficult to recruit than young women. 
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